Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment
Sponsor: Laekna Limited
This PHASE1/PHASE2 trial investigates Cervical Cancer and Endometrial Cancer and is currently completed. Laekna Limited leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Laekna Limited
For direct contact, visit the study record on ClinicalTrials.gov .